IONS — IONIS PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 874015 ·
Last close
$26.96
Market Cap
$4.49B
52W High
$86.74
52W Low
$26.55
ADV30
4,121,969
Next earnings
2026-11-09
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 242,721,000 239,399,000 -130,679,000 -109,971,000 2,912,590,000 296,303,000 2,518,950,000
Jun 2026 267,949,000 265,210,000 -102,297,000 -114,646,000 2,994,501,000 350,065,000 2,554,764,000
Mar 2026 246,091,000 243,091,000 -117,482,000 -92,528,000 3,449,969,000 173,381,000 2,958,555,000
Dec 2025 203,330,000 195,373,000 -214,473,000 -229,394,000 3,523,836,000 372,260,000 3,034,747,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-544,414,000
Investing CF
$240,688,000
Financing CF
$261,930,000
CapEx
$-78,352,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.32
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,948,340,000
Inventory
$28,578,000
Receivables
$88,340,000
ST Investments
$1,587,604,000
EBIT TTM
$-474,788,000
Pretax Income TTM
$-543,720,000
Interest Exp TTM
$68,932,000
Analysts
23

Yahoo Snapshot (yfinance, live)

Total Revenue
$960,092,032
EBITDA
$-548,548,992
Free Cash Flow
$-371,244,512
Enterprise Value
$5,071,705,600
Total Cash
$1,941,186,048
Total Debt
$2,173,091,072
Shares Out
166,545,100
Trailing EPS
$-3.35
Book Value
$2.37
ROE
-108.1%
ROA
-11.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 943,711,000 -381,717,000 -381,387,000 3,523,836,000 3,034,747,000 489,089,000 -268,583,000
Dec 2024 705,138,000 -475,107,000 -453,897,000 3,003,675,000 2,415,324,000 588,351,000 -500,947,000
Dec 2023 787,647,000 -353,730,000 -366,286,000 2,990,072,000 2,603,386,000 386,686,000 -307,513,000
Dec 2022 587,367,000 -410,191,000 -269,722,000 2,533,876,000 1,960,989,000 572,887,000 -274,370,000

TTM Snapshot

Revenues TTM
$874,090,000
NetIncome TTM
$-565,174,000
OpCashFlow TTM
—
Assets (Latest)
$2,994,501,000
Forward EPS
$-1.69

Max Pain — expiry 2027-01-15

max pain strike: $37.50 · spot: $27.39 · call oi: 4,679 · put oi: 5,260
Expected Move to 2027-01-15: ±$6.19 (22.60%) — implied range $21.20 – $33.58 · ATM straddle on $27.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EWTX Edgewise Therapeutics, Inc. $4.60B $42.04 —
KNSA Kiniksa Pharmaceuticals International, plc $4.64B $95.11 —
GIKLY Grifols SA $4.69B $5.55 —
INDV Supernus, Inc. $4.28B $36.28 —
COGT Cogent Biosciences, Inc. $4.85B $27.85 —

News headlines (Yahoo Finance, 1h cache)

Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease
2026-11-17 21:45 · Yahoo
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
2026-11-17 08:03 · Yahoo
Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start
2026-11-16 17:15 · Yahoo
The Strategy Exited Ionis Pharmaceuticals (IONS) Following Sequential Phase 3 Clinical Setbacks
2026-11-13 14:10 · Yahoo
Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
2026-11-12 15:00 · Yahoo
RNA Interference (RNAi) - Global Strategic Business Report: Capture the US$8 Billion 2032 Market as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec BioPharma, and Silence Therapeutics
2026-11-12 14:06 · Yahoo
Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings
2026-11-11 16:02 · Yahoo
Ionis to present at upcoming investor conferences
2026-11-10 12:05 · Yahoo
Ionis Pharmaceuticals Inc (IONS) (Q3 2026) Earnings Call Highlights: DAWNZERA Momentum and ...
2026-11-10 11:02 · Yahoo
Ionis Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-10 02:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.